First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Bookmark and Share
Published: 2 Jun 2014
Views: 2051
Dr Ramon Salazar - L'Hospitalet de Llobregat, Barcelona, Spain

Dr Salazar talks to ecancertv at ASCO 2014 about the results of the CALGB/SWOG 80405 study which suggest that the four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cancer and no KRAS mutations.

Read the article or watch the press conference for more. 

  • Categories: